We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen’s Combination Treatment Shows Promise in Colorectal Cancer Trial
Amgen’s Combination Treatment Shows Promise in Colorectal Cancer Trial
Amgen reported that adding its Vectibix (panitumumab) antibody to a cell proliferation blocker more than doubled response rates compared to the blocker alone in patients withKRAS G12C-mutated advanced colorectal cancer (CRC).